--- canonical_name: Convolvulus pluricaulis alternate_names: Shankhpushpi, Shankhapushpi, Samkhapushpi, Sankhaphuli, Shankhini, Sadaphuli, Convolvulus prostratus, Convolvulus microphyllus canonical_topic: Convolvulus pluricaulis for Health & Longevity short_topic_lc: convolvulus_pluricaulis creation_date: 2026-0825-1523 creator_ai_fullname: Opus 5 ep_keywords: Ayurvedic Herbs, Nootropics, Medhya Rasayana, Adaptogens --- # Convolvulus pluricaulis for Health & Longevity
Evidence Review created on 08/25/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5 **Also known as:** Shankhpushpi, Shankhapushpi, Samkhapushpi, Sankhaphuli, Shankhini, Sadaphuli, Convolvulus prostratus, Convolvulus microphyllus ## Motivation *Convolvulus pluricaulis* is a small, sprawling, white-flowered herb of the morning-glory family that grows in the dry sandy soils of the Indian subcontinent. In Ayurveda it sits in the group of plants used to sharpen intellect and steady the mind, and it is sold today as a dried powder, a syrup, a tablet or a concentrated extract marketed for memory, calm and sleep. Its appeal to people managing their own long-term brain health is obvious: an inexpensive, widely available plant with a long record of human use and a plausible effect on the chemistry of learning. Indian medical texts have described the plant for roughly two thousand years. Four botanically unrelated species still circulate in Indian markets under the same vernacular name, so what reaches a buyer is not always what the label claims. Laboratory and animal work on the plant is extensive; controlled work in people is almost absent, and the gap between those two bodies of evidence is the central question here. This review examines what is known about the plant's effects, how strong the evidence behind each claim is, where the risks and drug interactions lie, and how the material is dosed, sourced and monitored. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists non-systematic-review sources that give a high-level overview of *Convolvulus pluricaulis*, its constituents and its clinical standing. * [Shankhpushpi](https://www.alzdiscovery.org/cognitive-vitality/ratings/shankhpushpi) - Cognitive Vitality, Alzheimer's Drug Discovery Foundation The most candid third-party appraisal: it separates open-label human studies from controlled ones, flags the blood-pressure and phenytoin issues, and states the dose used. The foundation funds drug development and sells no supplements. * [Phytochemical Profile, Pharmacological Attributes and Medicinal Properties of Convolvulus prostratus - A Cognitive Enhancer Herb for the Management of Neurodegenerative Etiologies](https://pubmed.ncbi.nlm.nih.gov/32194410/) - Balkrishna et al., 2020 The fullest constituent-by-constituent map of the plant, with an explicit research-gap analysis. Written at Patanjali Research Institute, whose parent company sells Ayurvedic products, so its framing carries a direct commercial interest. * [An update on Shankhpushpi, a cognition-boosting Ayurvedic medicine](https://pubmed.ncbi.nlm.nih.gov/19912732/) - Sethiya et al., 2009 The reference account of the four-species identity problem, comparing the botany, chemistry and pharmacology of each plant sold as Shankhpushpi. Essential for understanding why trial results are hard to compare. * [Nootropic, anxiolytic and CNS-depressant studies on different plant sources of shankhpushpi](https://pubmed.ncbi.nlm.nih.gov/21846173/) - Malik et al., 2011 Tests all three main Shankhpushpi species head-to-head in one set of animal models of memory (nootropic action), anxiety and central nervous system depression - the basis for treating this species as the true source. * [Convolamine, a tropane alkaloid extracted from Convolvulus plauricalis, is a potent sigma-1 receptor-positive modulator with cognitive and neuroprotective properties](https://pubmed.ncbi.nlm.nih.gov/38011416/) - Crouzier et al., 2024 The single most mechanistically specific paper on the plant: it isolates one alkaloid, identifies its molecular target and reproduces the memory effect across three independent amnesia models. None of the six priority platforms - Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine and Lifespan.io - has published content on this herb. Both a general web search and an on-site or domain-restricted search were run for each, and all returned no relevant result; the herb is essentially absent from the English-language longevity press. ## Grokipedia * [Convolvulus prostratus](https://grokipedia.com/page/Convolvulus_prostratus) Covers the plant under its accepted botanical name, with taxonomy, distribution and traditional use in one place. Useful mainly for resolving the naming confusion between the several species sold as Shankhpushpi. ## Examine * [Convolvulus pluricaulis](https://examine.com/supplements/convolvulus-pluricaulis/) A short, deliberately deflationary summary: learning enhancement in healthy rodents at a potency near piracetam, sedation only at higher doses, and insufficient or contradictory evidence for mood. ## ConsumerLab ConsumerLab has published no product review, clinical update or dedicated report on *Convolvulus pluricaulis*. The herb appears only as one named ingredient inside an answer about a multi-ingredient blood-pressure formula, which is not a review of this intervention. No independent testing of single-ingredient Shankhpushpi products is available from this source. ## Systematic Reviews This section lists the systematic reviews and meta-analyses indexed on PubMed that cover *Convolvulus pluricaulis*. * [Role of Shankhpushpi (Convolvulus pluricaulis) in neurological disorders: An umbrella review covering evidence from ethnopharmacology to clinical studies](https://pubmed.ncbi.nlm.nih.gov/35878793/) - Sharma et al., 2022 The only systematic synthesis devoted to this species; pools traditional-use records (ethnopharmacology), preclinical pharmacology, toxicology and the sparse clinical data. * [Herbal Therapeutics for Alzheimer's Disease: Ancient Indian Medicine System from the Modern Viewpoint](https://pubmed.ncbi.nlm.nih.gov/36797613/) - Kushwah et al., 2023 Places the herb among ten Ayurvedic plants reviewed for Alzheimer's disease, which allows its mechanistic evidence to be ranked against better-studied alternatives. The trade-off here is a possible cognitive and calming gain set against loss of seizure control and product-quality hazards. The benefit side is represented by both papers above; the risk side is unrepresented, because no systematic review or meta-analysis of the herb's adverse effects, herb-drug interactions or contamination profile has been published. ## Mechanism of Action *Convolvulus pluricaulis* acts through several partly independent routes rather than one dominant pathway. The best-characterised is cholinergic. Its coumarins scopoletin and scopolin and the flavonoid kaempferol [inhibit acetylcholinesterase](https://pubmed.ncbi.nlm.nih.gov/25828605/) (the enzyme that clears acetylcholine, the brain's main memory-signalling chemical), raising acetylcholine at nerve junctions. Zebrafish modelling places that binding at both the catalytic and outer regulatory sites, implying [mixed competitive and non-competitive inhibition](https://pubmed.ncbi.nlm.nih.gov/35212831/). A second route is the sigma-1 receptor (a stress-sensing protein that supports nerve-cell survival). The plant's tropane alkaloid convolamine is a [positive modulator of that receptor](https://pubmed.ncbi.nlm.nih.gov/38011416/) and restored learning in three separate mouse amnesia models at roughly 1 mg/kg. A third route is antioxidant and inhibitory-signal traffic. In fruit flies the extract's effects [required superoxide dismutase](https://pubmed.ncbi.nlm.nih.gov/41602909/) (the cell's main defence against reactive oxygen), an ascorbate transporter, a glucose transporter and the GABA-B receptor (GABA is the brain's main calming signal), and vanished when any one was silenced. Functionally, four weeks of extract at 500 mg/kg [strengthened long-term potentiation](https://pubmed.ncbi.nlm.nih.gov/32282574/) (the durable strengthening of nerve connections that underlies memory) and weakened its mirror process in rat hippocampus. Competing readings exist. The same preparations are dose-dependently [sedative and muscle-relaxing](https://pubmed.ncbi.nlm.nih.gov/36825716/) in rodents, so the apparent memory gain may instead reflect lower anxiety and arousal rather than a specific pro-cognitive action. The two explanations have never been separated in people. No human pharmacokinetic study exists: absorption, half-life, tissue distribution and metabolising enzymes for scopoletin or convolamine are unreported. ## Historical Context & Evolution The plant's original use was not cognitive enhancement in healthy adults. Ayurvedic texts place it among the *Medhya Rasayana* (the intellect-promoting rejuvenatives) and prescribe it for epilepsy, insanity, hallucination, insomnia, chronic cough and burning sensations, usually in compound formulas rather than alone. Local Chinese and other indigenous systems used it for liver and infectious disease as well, as documented in the [modern reviews of the plant](https://pubmed.ncbi.nlm.nih.gov/25182446/). Interest in health optimisation followed the chemistry. [Isolation work beginning in 1948](https://pubmed.ncbi.nlm.nih.gov/18899765/) identified alkaloids and sterols, and from the 1960s onward pharmacologists reframed the herb as a nootropic rather than an anticonvulsant, because rodent learning models were cheap and its effects there were reproducible. Two findings changed the picture and are worth stating as findings, not verdicts. First, a 1992 investigation of [a Shankhapushpi preparation with phenytoin](https://pubmed.ncbi.nlm.nih.gov/1548901/) began with two patients losing seizure control; rat work then showed that single doses cut phenytoin's anticonvulsant effect without changing blood levels, while repeated dosing cut both. The same study found the preparation itself had significant anticonvulsant activity - a result that was never followed up. Second, [head-to-head testing of three of the species](https://pubmed.ncbi.nlm.nih.gov/21846173/) sold as Shankhpushpi found this one strongest for memory but, unlike the other two, inactive as an antidepressant. Scientific opinion has therefore narrowed rather than settled: the nootropic framing has firmed up, the antidepressant and antiepileptic claims remain open in both directions, and no placebo-controlled trial has yet tested either reading. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit of *Convolvulus pluricaulis* reaches this evidence level; no placebo-controlled trial of the herb has been published. ### Medium 🟩 🟩 No benefit reaches this evidence level either, for the same reason. ### Low 🟩 #### Long-Term Memory and Delayed Recall Two months of tablets improved delayed and recognition memory in healthy young adults in [an uncontrolled study](https://pubmed.ncbi.nlm.nih.gov/25861147/) and in [an open-label comparison against yoga](https://pubmed.ncbi.nlm.nih.gov/26170589/). The proposed basis is acetylcholinesterase inhibition. Neither study was blinded or placebo-controlled, both were single-centre, and participants were aged 16-25. **Magnitude:** In the uncontrolled study, auditory delayed recall improved 48% and visual delayed recall 44.9%, against 41.0% and 32.5% for the immediate-recall tests. #### Menopause-Related Symptom and Anxiety Burden A randomized pilot in 30 women after hysterectomy (surgical removal of the uterus) found powdered herb equal to *Asparagus racemosus* on menopause rating, symptom-index, quality-of-life and anxiety scales, with no change in serum oestrogen - so the effect is not oestrogenic. Small, active-controlled, no placebo arm, [single centre](https://pubmed.ncbi.nlm.nih.gov/42124828/). **Magnitude:** Direction is favourable and consistent across all four scales after 45 days at 6 g twice daily, with no advantage over the comparator; the trial reports significance levels only, so the literature gives no point-change figure. ### Speculative 🟨 #### Sleep Onset and Sedation Traditional use for insomnia is long-standing, and rodent work shows dose-dependent [central depression and reduced spontaneous movement](https://pubmed.ncbi.nlm.nih.gov/36825716/). No human sleep study exists, so the basis is animal and traditional only. #### Mood Elevation ⚠️ Conflicted Rodent despair models are [positive for one fraction](https://pubmed.ncbi.nlm.nih.gov/17599020/), but [direct comparison of the Shankhpushpi species](https://pubmed.ncbi.nlm.nih.gov/21846173/) found this one inactive while the other two worked. No human data. #### Reduced Alcohol Consumption and Withdrawal Anxiety Mice given the powder [drank less ethanol and showed less withdrawal anxiety](https://pubmed.ncbi.nlm.nih.gov/28479740/), an effect abolished by a GABA-A blocker. One animal study only; no human data. #### Blood Lipid Improvement Extract lowered cholesterol, triglycerides and a marker of artery-clogging risk in [an induced-hyperlipidaemia rat model](https://pubmed.ncbi.nlm.nih.gov/30182365/), only at the highest dose for cholesterol carried in the harmful particles. Animal-only; no human lipid study. #### Blood Pressure Lowering Ayurvedic practice uses the herb for hypertension, and blood pressure fell over 30 days in [an uncontrolled series](https://pubmed.ncbi.nlm.nih.gov/26605154/) of a six-herb powder containing it. Attribution to this herb alone is impossible. #### Glycemic Control ⚠️ Conflicted An [add-on human series](https://pubmed.ncbi.nlm.nih.gov/23559795/) reported larger fasting-glucose falls, but the herb [failed to reverse hyperglycaemia](https://pubmed.ncbi.nlm.nih.gov/32814671/) (high blood sugar) in diabetic rats. Cell work shows glucose-transporter upregulation. Confounded and contradictory. #### Neuroprotection Against Oxidative and Toxic Insults Extract shrank the damaged brain area and restored antioxidant enzymes after [experimental stroke](https://pubmed.ncbi.nlm.nih.gov/31743764/) and limited nerve damage in [chemotherapy-induced neuropathy](https://pubmed.ncbi.nlm.nih.gov/42576514/). Entirely animal; no human neuroprotection signal. #### Reduction of Alzheimer's Disease Markers Extract lowered tau and amyloid precursor protein (the two proteins that clump in Alzheimer's disease) in [rat brain](https://pubmed.ncbi.nlm.nih.gov/23112420/) and cleared tau while [extending lifespan in a fly model](https://pubmed.ncbi.nlm.nih.gov/29051039/). Animal and cell only. #### Gastric Mucosal Protection Fresh-plant juice matched sucralfate across four rat ulcer models by strengthening mucus defence rather than suppressing acid, in [one 2001 study](https://pubmed.ncbi.nlm.nih.gov/11491580/). Never replicated, and never tested in people. #### Seizure Threshold Elevation The [1992 preparation](https://pubmed.ncbi.nlm.nih.gov/1548901/) showed significant anticonvulsant activity against placebo in rats, but a [later extract](https://pubmed.ncbi.nlm.nih.gov/22280406/) only shortened recovery without abolishing seizures. Mechanistic and animal only. ## Benefit-Modifying Factors * **Baseline memory performance:** Both memory studies enrolled healthy 16-25-year-olds with normal baseline scores and still measured gains, so a low baseline is not required. Whether people with age-related decline respond at all is untested. * **Baseline blood pressure and thyroid status:** Low-normal blood pressure or borderline-low active thyroid hormone shifts the same pharmacology from neutral to unwanted, which caps the usable dose and therefore the achievable benefit. * **Sex:** The only randomized trial enrolled women exclusively, and it was a post-surgical menopause population. No trial has compared response between sexes, and no sex-specific effect has been characterised. * **Pre-existing health conditions:** Surgical menopause is the one condition with randomized evidence of benefit. In epilepsy the herb's effect on seizure control is unresolved in both directions, so benefit cannot be assumed there. * **Age-related considerations:** The cognitive studies stopped at 25 and the menopause trial enrolled adults after hysterectomy. Older adults, including those at the upper end of a longevity-oriented cohort, take more concurrent prescriptions and have stiffer blood-pressure regulation, both of which narrow the dose window. * **Genetic polymorphisms:** No pharmacogenetic variant has been linked to response. Variants in the enzymes that clear co-prescribed drugs - notably CYP2C9 and CYP2C19 (liver enzymes that clear phenytoin) - matter for interaction risk rather than for benefit. ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches this evidence level; no controlled safety trial of the herb has been published, and no fatal or organ-failure event has been attributed to it. ### Medium 🟥 🟥 #### Loss of Seizure Control When Combined with Phenytoin Routine monitoring caught breakthrough seizures and falling phenytoin levels in two patients taking a Shankhapushpi preparation; [rat work then reproduced both effects](https://pubmed.ncbi.nlm.nih.gov/1548901/), and the finding entered the standard [herb-drug interaction literature](https://pubmed.ncbi.nlm.nih.gov/10675182/). The preparation was a multi-herb syrup, so attribution to this species alone is not established - but the combination is the one hazard with human evidence, and breakthrough seizures are severe and immediate. **Magnitude:** Single-dose co-administration cut phenytoin's anticonvulsant effect without altering blood levels; repeated dosing cut both. The literature reports no percentage change in human phenytoin concentrations. #### Heavy-Metal Contamination of Ayurvedic Preparations Metals enter Ayurvedic products through *rasa shastra* (the deliberate combining of herbs with metals and minerals) and through poor sourcing. [Random purchase testing](https://pubmed.ncbi.nlm.nih.gov/18728265/) found lead, mercury or arsenic in a fifth of products from both US and Indian manufacturers. This is a category-level hazard, not one measured in single-ingredient Shankhpushpi specifically, and it is fully avoidable by certificate-verified sourcing. **Magnitude:** 20.7% of 193 internet-purchased Ayurvedic medicines (95% confidence interval, the range likely to contain the true value: 15.2-27.1%) contained detectable lead, mercury or arsenic, and every metal-containing product exceeded at least one acceptable daily intake standard. #### Botanical Substitution and Misidentification Four unrelated species trade under the same vernacular name, and over-exploitation has increased substitution. [Chromatographic marker profiling](https://pubmed.ncbi.nlm.nih.gov/25217706/) and [DNA-based species identification](https://pubmed.ncbi.nlm.nih.gov/27175337/) both show the material is routinely not what the label says. The consequence is pharmacological, not toxic: the substitutes have different and in some models opposite activity profiles. **Magnitude:** Marker-compound content differs several-fold between the four botanicals - stigmasterol ranged from 31.9 to 155.0 mg per gram of plant material across them - and the identification assay detects blending down to 10%. ### Low 🟥 #### Additive Blood-Pressure Lowering The herb mildly lowers blood pressure, and Ayurvedic practice uses it for hypertension. In [an uncontrolled 40-patient study](https://pubmed.ncbi.nlm.nih.gov/26605154/) of a six-herb powder containing it, blood pressure fell over 30 days. The concern is additive hypotension (abnormally low blood pressure) and dizziness on standing alongside antihypertensive drugs. Reversible on withdrawal. **Magnitude:** Direction is downward and the reported effect is mild; because no study isolates this herb from the other five in the formula, the literature gives no attributable millimetre-of-mercury figure. ### Speculative 🟨 #### Sedation and Psychomotor Slowing Rodent testing shows dose-dependent central depression, reduced grip strength and impaired motor coordination above the memory-enhancing dose range. No human adverse-event series exists; the basis is animal dose-response plus traditional use as a tranquilliser. #### Suppression of Active Thyroid Hormone Root extract lowered circulating active thyroid hormone in mice by [inhibiting the enzyme that converts the storage form to it](https://pubmed.ncbi.nlm.nih.gov/11280709/). Isolated animal report, one species, one extract; no human thyroid measurement has been published. #### Additive Blood-Glucose Lowering Cell work shows upregulation of the glucose transporter and PPAR-γ (a gene switch controlling fat-cell formation and insulin sensitivity). The inferred hazard - hypoglycaemia (low blood sugar) with glucose-lowering drugs - rests on mechanism only. ## Risk-Modifying Factors * **Genetic polymorphisms:** Poor-metaboliser variants of CYP2C9 and CYP2C19 leave less pharmacokinetic headroom, so any herb-driven fall in phenytoin effect is less well tolerated. No variant has been studied for the herb itself. * **Baseline biomarker levels:** Low-normal seated blood pressure, low-normal active thyroid hormone or a phenytoin level already near the bottom of its range each convert a mild pharmacological nudge into a clinically relevant one. * **Sex-based differences:** None have been characterised. The only randomized safety exposure is in women after hysterectomy at 6 g twice daily for 45 days; no comparable male exposure has been reported at any dose. * **Pre-existing health conditions:** Epilepsy, treated hypertension, hypotension, hypothyroidism (an underactive thyroid) on replacement, and diabetes on glucose-lowering drugs all amplify the documented and inferred hazards. Pregnancy and lactation are wholly untested. * **Age-related considerations:** Beyond the post-hysterectomy trial, documented exposure stops at age 25. Older users carry more interacting prescriptions and blunted blood-pressure reflexes, so the dizziness-on-standing risk is highest at the upper end of the target range. ## Key Interactions & Contraindications * **Phenytoin (absolute contraindication):** Co-use reduced anticonvulsant effect and lowered plasma levels, with breakthrough seizures in two patients. The combination is an absolute contraindication; where it is already in place, the documented mitigation is phenytoin level monitoring and neurology review before either agent is stopped. * **Other anti-seizure medications (caution):** Carbamazepine, valproate, lamotrigine and levetiracetam have not been tested with the herb. Because the phenytoin effect was partly pharmacodynamic rather than metabolic, class-wide caution applies, and seizure frequency rather than levels alone is the informative marker. * **Antihypertensive drugs (caution):** ACE inhibitors (lisinopril) and angiotensin receptor blockers (losartan) both blunt a blood-pressure hormone; calcium channel blockers (amlodipine) relax vessel walls; thiazide diuretics (indapamide) shed fluid. All can produce additive hypotension. Mitigations are staggered dosing and home blood-pressure logs. * **Sedatives and central depressants (caution):** Benzodiazepines (calming prescriptions: diazepam, alprazolam), Z-drugs (sleep prescriptions: zolpidem, zopiclone), opioids (strong painkillers: oxycodone, tramadol) and alcohol may be potentiated. Consequence is excess drowsiness and impaired coordination, avoided by not stacking same-evening. * **Levothyroxine and thyroid replacement (monitor):** Animal inhibition of storage-to-active thyroid hormone conversion could blunt replacement, with fatigue and cold intolerance as consequences. The documented mitigation is a recheck of thyroid-stimulating hormone and active thyroid hormone 8-12 weeks after starting. * **Glucose-lowering drugs (monitor):** Metformin, sulfonylureas (insulin-releasing tablets: glipizide, glimepiride) and insulin carry a theoretical additive hypoglycaemia risk from the herb's glucose-transporter effects. Consequence is low blood sugar, with more frequent glucose checks in the first month as the documented mitigation. * **Over-the-counter medications (caution):** Sedating antihistamines used as sleep aids (diphenhydramine, doxylamine) and dextromethorphan-containing cough products add to the sedative load. Consequence is next-morning impairment, separated in practice by dosing the herb on nights these are not used. * **Supplement interactions (caution):** Additive sedation with valerian, kava, magnesium glycinate, melatonin and L-Theanine. Additive cholinergic load with huperzine A, *Bacopa monnieri* and alpha-GPC, which can cause headache, cramping or vivid dreams. Consequence is amplified, not novel, effects. * **Supplements with additive blood-pressure lowering (caution):** *Rauvolfia serpentina*, beetroot nitrate, hibiscus, aged garlic extract and high-dose omega-3 all lower blood pressure, so stacking them with this herb risks symptomatic hypotension and dizziness on standing. Some marketed blood-pressure formulas already contain both this herb and *Rauvolfia*. * **Other interventions (caution):** Anaesthesia and any intervention requiring stable blood pressure or seizure threshold - elective surgery, electroconvulsive therapy, ketogenic or extended-fasting protocols that themselves lower blood pressure. The documented mitigation is suspension of the herb two weeks beforehand. **Populations who should avoid Convolvulus pluricaulis:** * Anyone taking phenytoin, or with epilepsy of any type not stably controlled for 12 months * Pregnancy and lactation, at any dose, on grounds of complete absence of reproductive data * Symptomatic hypotension, or seated systolic blood pressure below 100 mmHg * Untreated or under-replaced hypothyroidism, defined as thyroid-stimulating hormone above 4.0 mIU/L * Scheduled surgery or general anaesthesia within 14 days * Children and adolescents under 16, the lower bound of every human study of the single herb ## Risk Mitigation Strategies * **Outright exclusion of phenytoin co-use:** The one documented human harm is loss of seizure control. Protocols screen the full medication list before starting and treat any anti-seizure prescription as a stop signal rather than a monitoring problem. * **Species-verified material:** A certificate naming *Convolvulus pluricaulis* or *Convolvulus prostratus* with chromatographic or DNA confirmation prevents receiving *Clitoria ternatea*, *Evolvulus alsinoides* or *Canscora decussata*, whose activity profiles differ. * **Heavy-metal certificate of analysis:** Batch lead, mercury and arsenic figures below 0.5 micrograms per daily serving, together with exclusion of *rasa shastra* and mineral-containing formulas, address the one-in-five contamination rate found in purchase testing. * **Low entry dose with titration over 2-3 weeks:** Protocols begin at 1-2 g of powder daily. Sedation, motor slowing and blood-pressure lowering are dose-dependent in animals, which a low entry dose surfaces early; trial doses reached 6 g twice daily. * **Evening dosing for the first two weeks:** This shifts any unrecognised sedation into the sleep window and prevents daytime psychomotor impairment. Driving and high-skill training within four hours of the first three doses carry the residual risk. * **Seated and standing blood-pressure log, twice weekly for the first month:** A fall greater than 20 mmHg systolic on standing indicates additive hypotension; catching it early prevents falls, the practical consequence of dizziness on standing. * **Thyroid recheck at 8-12 weeks:** A repeat of thyroid-stimulating hormone and active thyroid hormone detects the animal-model suppression of storage-to-active conversion before fatigue or cold intolerance is misread as a separate problem. * **Fixed 8-week decision point:** Both human studies measured memory change at two months. A predefined stop-or-continue review prevents indefinite exposure to an intervention whose long-term safety has never been measured. ## Therapeutic Protocol * **Whole-powder course (traditional Ayurvedic approach):** 3-6 g of dried whole-plant powder twice daily with warm water or milk after food. The randomized menopause pilot used 6 g twice daily for 45 days, the highest verified human dose. * **Processed-tablet course:** 500 mg tablets twice daily after food with milk, for two months. Both human cognitive studies used tablets prepared by grinding the powder three times with the plant's own fresh juice. * **Standardised-extract course (pharmaceutical approach):** Hydroalcoholic or methanolic extracts standardised to scopoletin, dosed far lower than crude powder. No human dose has been established; all extract dosing derives from rodent work at 100-500 mg/kg. * **Competing approaches:** Ayurvedic groups at Gujarat Ayurved University favour whole-plant juice-processed tablets; pharmacology groups, including the commercially affiliated Patanjali Research Institute, favour standardised extracts. Neither approach has been tested against the other in people. * **Best time of day:** Evening for calming and sleep use, given the animal sedative profile; morning for cognitive use. Every human study dosed twice daily after food, so a fed state is the only validated condition. * **Half-life:** Unknown. No human pharmacokinetic study of the plant or of scopoletin, scopolin or convolamine exists, so dosing intervals in all protocols are conventional rather than derived. * **Single versus split dosing:** Split, twice daily. Every human study used a divided schedule; no single-daily-dose exposure has been reported, and the absent half-life data give no basis for consolidating it. * **Genetic polymorphisms:** No variant has been shown to influence dose. CYP2C9 and CYP2C19 status matters only for the phenytoin interaction, which is a contraindication rather than a dose adjustment. * **Sex-based differences:** No dosing difference is established. The 6 g twice-daily exposure was validated in women only; no male cohort has been dosed above the 500 mg twice-daily tablet level. * **Age-related considerations:** All human dosing was in 16-25-year-olds or in adult women after hysterectomy. For older users, the lower end of each range is the only defensible starting point, given blunted blood-pressure reflexes. * **Baseline biomarker levels:** Seated blood pressure, thyroid-stimulating hormone and, where relevant, fasting glucose set the usable dose ceiling. Low-normal values on any of them argue for the 1-2 g entry dose rather than trial-level dosing. * **Pre-existing health conditions:** Treated hypertension, hypothyroidism and diabetes all call for the lower dose range plus the monitoring cadence below. Surgical menopause is the only condition with a validated full-dose protocol. ## Discontinuation & Cycling * **Intended duration:** Short-to-medium term, not lifelong. The traditional *rasayana* framing is a defined course; the longest documented human exposure is 60 days, so continuous multi-year use is entirely unstudied. * **Withdrawal effects:** None documented. No human study reported rebound insomnia, anxiety or seizure activity on stopping, and no animal withdrawal syndrome has been described for the extract. * **Tapering protocol:** No taper data exist. Both human studies ended dosing abruptly at the study endpoint without reported incident, so abrupt cessation appears uneventful; a one-week step-down remains a reasonable precaution for those on sedatives. * **Cycling for sustained effect:** No tolerance has been demonstrated, so cycling has no efficacy rationale. Its only defensible purpose is limiting cumulative exposure - for example 8 weeks on, 4 weeks off - given the absent long-term safety data. * **Mandatory interruptions:** A 14-day gap before elective surgery or general anaesthesia is standard, because of the blood-pressure-lowering and sedative effects and the unmeasured interaction with anaesthetic agents. ## Sourcing and Quality * **Species verification is the first filter:** A certificate naming *Convolvulus pluricaulis* or its synonym *Convolvulus prostratus*, backed by chromatographic fingerprinting or the internal-transcribed-spacer DNA assay, is what identifies the material. Vernacular "Shankhpushpi" labelling alone indicates nothing about the species supplied. * **Plant part matters:** Human studies used the whole plant, *panchanga*, harvested in flower. Root-only material was what suppressed active thyroid hormone in mice; leaf-only extracts were the sedation and anxiety models. Whole-plant material is therefore what matches the human dosing. * **Marker standardisation:** A stated scopoletin content is the informative label figure, since that marker is the one most closely tied to acetylcholinesterase inhibition and to the synaptic-plasticity effect. Unstandardised powder varies with harvest stage, as scopoletin accumulation changes across the growth cycle. * **Third-party testing is the decisive filter:** Batch lead, mercury and arsenic results from an independent laboratory - NSF International, US Pharmacopeia or an equivalent accredited testing house - are what address the fifth of Ayurvedic products carrying detectable toxic metals. * **Mineral-containing formulations:** Preparations described as *bhasma*, *rasa* or herbo-mineral compounds carried both a higher prevalence of metals and far higher median lead and mercury concentrations than plant-only preparations. * **Brands and formats:** Single-ingredient powders and tablets from established Indian manufacturers - Himalaya Wellness, Dabur, Baidyanath, Patanjali Ayurved - and from Western suppliers such as Banyan Botanicals are the common options. Patanjali also authors much of the primary literature, a direct commercial interest. * **Undisclosed multi-herb syrups:** The one documented human harm involved a compound Shankhapushpi syrup of unstated composition. Formulas that do not name every constituent and its quantity make both dosing and attribution of any adverse effect impossible. ## Practical Considerations * **Time to effect:** Sedative and calming effects appear within hours of the first doses. Memory changes were measured only at 45-60 days in every human study, so a fair evaluation window is two months, not two weeks. * **Common pitfalls:** Buying a different species under the same vernacular name; stacking it on antihypertensive or sedative drugs without adjusting either; expecting drug-like cognitive effects from an intervention with no placebo-controlled evidence; and using multi-herb syrups that make attribution impossible. * **Regulatory status:** In the United States it is a dietary supplement, with no Food and Drug Administration review of efficacy or safety. In India it is a licensed Ayurvedic drug under the Ministry of Ayush, which is why its trials register nationally. * **Cost and accessibility:** Neither expensive nor hard to obtain - crude powder typically costs a few US dollars per month. The cost that matters is the analytical premium for species-verified, metal-tested material, which can multiply the price several-fold. * **Quality of the evidence base as a practical constraint:** Almost all primary research comes from institutions whose remit is validating Ayurveda, and the herb is unpatentable, so no party has a commercial reason to fund a definitive placebo-controlled trial. ## Interaction with Foundational Habits * **Sleep:** Potentiating and direct. Animal models show dose-dependent central depression and reduced spontaneous movement, and traditional use targets insomnia. Practically, evening dosing, no same-night stacking with sedating antihistamines, melatonin or alcohol, and any daytime drowsiness signalling a dose above the individual's threshold. * **Nutrition:** Indirect and mild. Every human study dosed after food, traditionally with warm milk, which plausibly aids absorption of the plant's sterols and coumarins; there is no fasting requirement and no documented nutrient depletion. No food needs avoiding, but taking it on an empty stomach departs from all validated dosing. * **Exercise:** Blunting, potentially, with no direct data. The rodent grip-strength and motor-coordination decrements at higher doses argue against dosing before heavy lifting, sprinting or any skill-dependent session. Nothing suggests it blunts hypertrophy or endurance adaptation; the concern is acute coordination, not training response. * **Stress management:** Direct and potentiating. Extract [reduced pro-inflammatory signalling and restored serotonin and noradrenaline](https://pubmed.ncbi.nlm.nih.gov/30551424/) in chronically stressed rats, and it improved anxiety scores in the menopause pilot. It complements breathwork and meditation rather than replacing them - in the comparative trial, yoga outperformed the herb on short-term recall. ## Monitoring Protocol & Defining Success Baseline testing before the first dose has two purposes: establishing the values that set the dose ceiling, and creating the comparison points that make any later change interpretable. The baseline panel is a fasting draw covering thyroid function, glucose and lipids, with whole-blood lead added where the product's contamination testing is unavailable, and seated and standing blood pressure recorded on two separate days rather than once. Phenytoin use is an exclusion rather than a monitoring problem; use of another anti-seizure drug calls for a documented baseline seizure frequency. Ongoing monitoring follows a front-loaded cadence: blood pressure twice weekly for the first four weeks, then monthly; thyroid function and glucose at 8-12 weeks; lipids and liver enzymes at 12 weeks; then every 6-12 months for as long as use continues. Success is defined as a measurable gain on the tracked cognitive or symptom marker with every safety marker unchanged. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |---|---|---|---| | Seated blood pressure | 110-125 / 70-80 mmHg | The herb lowers blood pressure; detects additive drops | Measured seated, then after 2 minutes standing. A fall over 20 mmHg systolic on standing indicates orthostatic hypotension - dizziness caused by a blood-pressure drop on rising | | Thyroid-stimulating hormone | 0.5-2.0 mIU/L | Screens for the thyroid suppression seen in animals | Thyroid-stimulating hormone is the pituitary signal that drives the thyroid. Drawn fasting before 10 a.m.; conventional reference range extends to 4.0-4.5 mIU/L, which is far wider | | Free T3 | 3.2-4.2 pg/mL | The specific hormone reduced in the animal study | Free T3 is the active thyroid hormone; free T4 is its storage precursor. Both are measured together, since the animal effect was on conversion between them. Conventional range 2.0-4.4 pg/mL | | Fasting glucose | 75-86 mg/dL | Guards against additive lowering with diabetes drugs | 8-12 hour fast. Conventional normal range runs to 99 mg/dL, which is far wider. Paired with HbA1c - glycated haemoglobin, a three-month average of blood sugar - optimally below 5.3% | | LDL cholesterol | Below 100 mg/dL, or below 70 mg/dL with added cardiovascular risk | Tracks the animal lipid-lowering signal in humans | LDL is the cholesterol carried in the harmful particles. 9-12 hour fast; paired with apolipoprotein B and triglycerides. Conventional cut-off is 130 mg/dL | | ALT | 10-26 U/L in women, 10-33 U/L in men | Herbal products can cause unpredictable liver injury | ALT is alanine aminotransferase, a liver enzyme; paired with AST, aspartate aminotransferase. Conventional upper limits reach 40-55 U/L, which misses early injury | | Whole-blood lead | Below 1.0 µg/dL | One-fifth of Ayurvedic products carry detectable lead | No fasting needed. The Centers for Disease Control and Prevention reference value is 3.5 µg/dL, a population screening threshold rather than a target | | Plasma phenytoin | 10-20 µg/mL total, only where phenytoin cannot be stopped | Co-use lowered levels and broke through seizure control | Trough sample immediately before the morning dose. Where albumin is low, free phenytoin is measured instead, target 1-2 µg/mL | | Delayed-recall test score | No established target; the change from the individual's own baseline is what is tracked | The endpoint that both human studies actually moved | The same standardised memory instrument is used at baseline, 4 weeks and 8 weeks, at a consistent time of day, since sedation depresses scores | Qualitative markers worth tracking alongside the labs: * Sleep latency and whether sleep feels deeper or merely longer * Morning alertness, and any next-day grogginess after evening dosing * Subjective calm under load, distinguished from flatness or indifference * Recall of names, lists and where objects were placed * Steadiness on standing quickly, and any lightheadedness * Coordination and reaction quality in skill-dependent training ## Emerging Research * **No registered interventional trials:** A ClinicalTrials.gov search on 17 August 2026 for the species and all its synonyms returned zero studies. Trials in India's Ayurvedic domain register with the [Clinical Trial Registry - India](https://ctri.nic.in/Clinicaltrials/index.jsp) instead, so international registry searches understate activity. * **First randomized signal:** [Budihal et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42124828/) randomized 30 women after hysterectomy to the herb or *Asparagus racemosus*, 6 g twice daily for 45 days. A placebo-controlled replication would settle whether the improvement exceeds what an unblinded design produces anyway. * **Sigma-1 receptor pharmacology:** [Crouzier et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38011416/) identified convolamine as a positive modulator of this receptor, active at roughly 1 mg/kg across three mouse amnesia models. A named molecular target makes a licensable single-agent trial conceivable. * **Conserved antioxidant and calming pathways:** [Mitra et al., 2026](https://pubmed.ncbi.nlm.nih.gov/41602909/) showed the extract's effects in fruit flies depend on superoxide dismutase, a glucose transporter, an ascorbate transporter and the GABA-B receptor, and that vitamin C alone reproduced them - which would weaken the case for the herb specifically. * **Metabolic direction:** [Melloni et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37049568/) found the extract upregulates PPAR-γ and the glucose transporter GLUT-4 in fat cells while suppressing inflammatory signalling, opening a glucose-control line of enquiry that has never been tested in people. * **Peripheral nerve protection:** [Ali et al., 2026](https://pubmed.ncbi.nlm.nih.gov/42576514/) reported reduced hyperalgesia (heightened pain sensitivity) and preserved nerve architecture in chemotherapy-induced neuropathy in rats at 200 mg/kg. This is a new indication rather than an extension of the cognitive claim. * **Evidence that could weaken the case:** [Malik et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21846173/) found this species inactive as an antidepressant while its two namesakes worked, and [Garg et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32814671/) found it failed to reverse hyperglycaemia in diabetic rats despite lowering lipids. * **Funding structure as a research constraint:** The herb is cheap and unpatentable, so no manufacturer can recover the cost of a definitive trial, and institutional payers have no stake in an intervention bought out of pocket. That asymmetry, not scientific doubt, is the likeliest reason the evidence base has stalled at open-label studies. * **Where a decisive result would come from:** A blinded, placebo-controlled trial of species-verified, marker-standardised whole plant, powered for delayed recall over 12 weeks, with phenytoin users excluded and thyroid function as a safety endpoint. Nothing of that design is currently registered anywhere. ## Conclusion *Convolvulus pluricaulis* is an inexpensive Indian herb with a two-thousand-year record of use for memory and calm, and a modern research base that is broad in animals and thin in people. The laboratory story is coherent: the plant raises the brain's main memory-signalling chemical, engages a nerve-survival protein, and strengthens the connection changes that underlie learning. The human story is much smaller. Studies in young adults reported better delayed recall after two months, though everyone involved knew what was being taken, and one small randomized trial in women after surgical menopause found relief of symptoms and anxiety equal to another herb. Nothing has been tested against a placebo. The risks are specific rather than diffuse. One combination - with the anti-seizure drug phenytoin - has produced breakthrough seizures in people, the only harm here with direct human evidence. Two further hazards belong to the product rather than the plant: a fifth of Ayurvedic preparations carry detectable toxic metals, and four unrelated species are sold under the same common name, so verified identity and independent metal testing matter more here than dose refinement. Mild blood-pressure lowering, sedation and an animal-level thyroid effect are all manageable with monitoring. Most of the research comes from institutions whose purpose is validating Ayurveda, and some of it from a company that sells the product. The plant is also cheap and unpatentable, so it draws no commercial research funding. The evidence remains genuinely uncertain rather than negative. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**